AstraZeneca upgraded to Hold from Sell at Deutsche Bank (earlier)

Deutsche Bank earlier today upgraded AstraZeneca to Hold from Sell with a price target of 10,500 GBp, up from 9,500 GBp. The announced dividend increase addresses one of Deutsche’s main concerns, the analyst tells investors in a research note. The firm, however, still has questions around AstraZeneca’s innovation outlook and its “expansive bolt-on approach.